Last reviewed · How we verify
AZD8601
AZD8601 is a selective and potent inhibitor of the PI3K gamma isoform.
AZD8601 is a selective and potent inhibitor of the PI3K gamma isoform. Used for Treatment of rheumatoid arthritis.
At a glance
| Generic name | AZD8601 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K gamma inhibitor |
| Target | PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PI3K gamma, AZD8601 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.
Approved indications
- Treatment of rheumatoid arthritis
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- AZD8601 Study in CABG Patients (PHASE2)
- Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |